705TiP Phase II trial of retifanlimab (anti–PD-1) in combination with INCAGN02385 (anti–LAG-3) and INCAGN02390 (anti-TIM-3) as first-line treatment in patients with PD-L1-positive recurrent/metastatic squamous cell carcinoma of the head and neck

Autor:	C. Le Tourneau, L.F. Licitra, N. Bourayou, R. Schaub, M. Bartenstein, W. Wei, E.E.W. Cohen
Rok vydání:	2022
Předmět:	Oncology Hematology
Zdroj:	Annals of Oncology. 33:S865
ISSN:	0923-7534
DOI:	10.1016/j.annonc.2022.07.829
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::4e245fef4ca7f67d66dcf6fd3094e072 https://doi.org/10.1016/j.annonc.2022.07.829 Zobrazit plný text záznamu